Cytokinetics Announces the Initiation of a First-Time-In-Humans, Phase I Clinical Trial of CK-2017357
Cytokinetics, Incorporated announced that the company has initiated a first-time-in-humans, Phase I clinical trial of CK-2017357 in healthy male volunteers. CK-2017357 is a fast skeletal muscle troponin activator and is the lead drug candidate that has emerged from the company’s skeletal sarcomere activator program. CK-2017357 selectively activates the troponin complex and increases its sensitivity to calcium, subsequently leading to an increase in skeletal muscle force. [more...]
|
|
|
